# Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

> **NCT06539559** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Wang Jiayu** · enrollment: 60 (estimated)

## Conditions studied

- Breast Neoplasms
- Neoplasm Metastasis
- Drug Therapy
- Bevacizumab

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06539559
- **Lead sponsor:** Wang Jiayu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06539559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06539559, "Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06539559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*